Building manufacturing capacity - the chapter and verse
Article Abstract:
The biopharmaceutical industry's manufacturing capacity has moved through three discrete chapters in its 25-year history to 2006's $50 billion market. It is believed that the formal capacity sharing adopted in the year 2006 might provide a powerful method to manage risk across product pipelines and a shared biomanufacturing operation could build considerable efficiencies, leading to dramatic human health improvements in less time.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Fates intertwined
Article Abstract:
The fates of biotechnology and pharmaceuticals and also the problems faced by these two sectors are discussed. Pharmaceutical industry can address many of its problems by adopting biotechnology, as biotechnology companies can contribute to both the necessary scientific focus and the technological means to improve industrial productivity.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Whither agbiotechnology?
Article Abstract:
The applications of agriculture biotechnology in the future are discussed. The products that will dominate in 2016 and the different challenges that should be overcome for this doubly green revolution to come to pass are illustrated.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Using financial accounting information in the governance of takeovers: an analysis by the type of acquirer. Do managers credibly use accruals to signal private information? Evidence from the pricing of discretionary accruals around stock splits
- Abstracts: Chiron's manufacturing misfortunes boost competitors. Diversa restructures, raining question over bioprospecting
- Abstracts: Attention turns to the new wave. Kicking the oil habit
- Abstracts: Deconstructing Myogen's market cap. Niche indications could drive higher valuations. Are small biotechs still underselling themselves?
- Abstracts: Gold in the ivory tower: Equity rewards of outlicensing. Who took the tech out of biotech? The hermit crab solution